Hematology-Oncology
Latest news
316 articles · 20 / page
Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors
A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can
急性白血病危重成人患者的時間趨勢和預後因素：個體參與者數據薈萃分析
這項涵蓋19國55個ICU的2003名患者研究發現，急性白血病危重患者總體ICU死亡率為45%，需機械通氣者達66%。年齡>65歲、AML診斷、化療期間入院等因素顯著增加死亡風險，但隨時間推移生存率有所改善。
Optimizing Busulfan Precision Dosing: A Synthesis of Real-World Pharmacokinetics, Obesity, and Drug Interactions
This review synthesizes clinical evidence on busulfan pharmacokinetics, highlighting the critical role of TDM, the impact of body weight normalization, and significant drug interactions with deferasirox.
Ethnicity Influences Relapse-Free Survival in Immune-Mediated Thrombotic Thrombocytopenic Purpura
A French study reveals African ancestry significantly increases relapse risk in iTTP patients treated with rituximab. Key risk factors include male sex and prior relapses, with implications for personalized monitoring strategies.
TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms
A multicenter retrospective study suggests that MDS with isolated del(5q) and TP53 multihit alterations has substantially better survival than other low-blast TP53-multihit MDS, challenging how this subgroup should be classified.
Bone Marrow Immune Profiling Identifies a Practical Infection Risk Score in Multiple Myeloma
A large multicenter study links specific bone marrow immune cell patterns to infection risk in multiple myeloma and proposes a clinically relevant immune score that may support minimally invasive monitoring.
Hematologic Response to Iron Therapy and Stillbirth Risk in Moderate Iron Deficiency Anemia
Study reveals inadequate hemoglobin improvement at 20-24 weeks after iron therapy increases stillbirth and preterm birth risks in moderate iron deficiency anemia pregnancies, highlighting need for early intervention.
Reduced-Intensity Thiotepa Plus Post-Transplant Cyclophosphamide Delivers Near-Universal Engraftment and Minimal GVHD in Matched Sibling Transplantation for Adolescents and Adults With Sickle Cell Disease
A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.
Alpha-1-Antitrypsin Emerges as a Potential Salvage Option for Steroid- and Ruxolitinib-Refractory Gastrointestinal Acute GVHD
A 2026 single-center retrospective study suggests alpha-1-antitrypsin may offer favorable safety and encouraging activity in heavily pretreated gastrointestinal acute GVHD, though detailed outcome data and external validation remain essenti
MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source
A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.
Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma
In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell tra
Addressing the Palliative Care Gap in Adolescent and Young Adult Cancer Patients Receiving Medical Assistance in Dying
This cohort study highlights the underutilization of timely palliative care in adolescent and young adult cancer patients opting for MAID, with significant symptom burden and complex psychosocial factors influencing end-of-life decisions.
Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1
A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn’t impact overall survival.
Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial
Baseline ctDNA levels predict early progression and poor survival in untreated follicular lymphoma, outperforming traditional risk scores like FLIPI. This study highlights ctDNA’s potential as a stratification tool in clinical trials.
Optimizing CML Management: Clinical Synthesis of the ASC4OPT Study and the Allosteric Inhibition Paradigm
This review synthesizes the ASC4OPT trial results alongside pivotal evidence from the ASCEMBL and ASC4FIRST studies, evaluating the role of the STAMP inhibitor asciminib in chronic myeloid leukemia across multiple treatment lines.
Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant
VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, demonstrated acceptable safety and preliminary efficacy in relapsed/refractory AML/MDS after allogeneic HCT, with 20% overall response rate and manageable toxicities.
Clonal Lymphocyte Expansions and JAK-STAT Mutations Drive Refractory Celiac Disease
This study uncovers clonal lymphocyte expansions and JAK-STAT pathway mutations as key drivers of refractory celiac disease, suggesting a shared pathogenic continuum between RCD1 and RCD2 while cautioning against JAK inhibitor monotherapy d
Blocking P2Y14R Emerges to Combat Venous Thromboembolism via Neutrophil-Plaque Interaction
New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.
2/20/20 Model Outperforms AQUILA Criteria in Identifying High-Risk Smoldering Multiple Myeloma
The 2/20/20 risk stratification model identifies a smaller, truly high-risk SMM group with higher progression rates than the AQUILA trial criteria, suggesting better targeting for early intervention.
Revolutionizing iTTP Treatment: Reverse CAR T Cells Target Autoreactive B Cells with Precision
A groundbreaking study introduces reverse CAR T cells to selectively deplete anti-ADAMTS13 autoreactive B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP), offering a novel, precise, and potentially safer therapeutic appr
Browse by specialty
Open language-specific specialty feeds and department pages.